

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16086923				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Complement factor B, CFB, gapmer, oligomer, oligonucleotide, MOE, cEt		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 48/00		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas	Categorías especiales de los documentos citados***
SIPI	No se encontraron documentos que puedan afectar la patentabilidad de la solicitud	-	-	-
ISA/USPTO	WO 2008/036841	27/03/2008	-	A
	US 2010/0120665	13/05/2010	-	A
	US 2005/0107319	19/05/2005	-	A
	US 2008/0085869	10/04/2008	-	A
	Vaculik <i>et al.</i> (2008)	07/11/2008	-	A
EPO	WO 2004/103288	02/12/2004	-	A
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente	Vaculik, C., Rüger, B. M., Yanagida, G., Hollemann, D., Soleiman, A., Losert, U. M., Chen, J., Fischer, M. B. 2008. Shift of C3 deposition from localization in the glomerulus into the tubulo-interstitial compartment in the absence of secreted IgM in immune complex glomerulonephritis. <i>Clin Exp Immunol.</i> , Vol. 151 (1), Pág: 146-154
-----------------------	--

Fecha del reporte de búsqueda:	27/Abril/2018
--------------------------------	---------------

Búsqueda en PatBase



Username: SIC9@patbase.com
Subaccount: Tatiana Vargas

Menu - Search - History - Session - Folder - Order Help - Logoff

#	Search query	Results	Options
11	TAC=(1) and PA=(ionis)	3	View Browse Hits Optimise more...
10	PA=(ionis)	568	View Browse Hits Optimise more...
9	[SP]: 1.-94. (canceled) 95. a compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of seq id nos: 198, 228, 237, 440, 444, 448, 450, 453, 455, 549, and 598. 96. the compound of claim 95, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides having a nucleobase sequence comprising any of the nucleobase sequences of se... show full search	0	
8	TAC=(7 and 1)	0	
7	TAC=(6 and (cEt or (constrain* w2 ethyl)))	26	View Browse Hits Optimise more...
6	TAC=(5 and (moe or (2-O-methox**)))	95	View Browse Hits Optimise more...
5	TAC=(modif* and oligomer*)	11005	View Browse Hits Optimise more...
4	TAC=(1 and oligomer*)	26	View Browse Hits Optimise more...
3	TAC=(1 and (gapmer or oligonuc**))	24	View Browse Hits Optimise more...
2	TAC=(1 and (inter**))	104	View Browse Hits Optimise more...
1	TAC=((complement w3 factor B) or CFB)	1563	View Browse Hits Optimise more...

Information | Shortcuts

Command Reference

Bibliographic data
Textual data
Update commands
Operators
Navigation / shortcuts

Search tools

Patent Number Formats
PatBase Thesaurus
Classification Finder

Register for a Webinar

European Training Courses

Video tutorials

Búsqueda Epoquenet

2/7 © EPODOC / EPO

PN - [CN102140470](#) A 20110803

PNFP - CN102140470B B 20130918

PR - CN20101613022 20101230

AP - CN20101613022 20101230

DT - I

CT - || STSE (A)
[WO2009149182](#) A1 20091210 [] (UNIV TEXAS [US], et al)
[CN101507821](#) A 20090819 [] (GEN HOSPITAL TIANJIN MEDICAL U [CN])
[CN101792793](#) A 20100804 [] (UNIV CENTRAL SOUTH)
[XP002559294](#) A 00000000 [A]

CTNP - || STSE (A)
[A] Eugene Berezikov等, "Mammalian Mirtron Genes", <<Molecular Cell>>, (20071026), vol. 28, no. 2, doi:doi:[10.1016/j.molcel.2007.09.028](#), PAGE 328 - 336, XP002559294
[A] 1-6
328-336
[A] 石磊等, "探讨人胶质瘤细胞系U87细胞中反义miR-21诱导凋亡机制", <<中华医学遗传学杂志>>, (20081031), vol. 25, no. 5, PAGE 497 - 501
[A] 1-6
497-501

PA - (A B)
SUZHOU GENEPHARMA CO LTD; SHANGHAI INST MATERIA MEDICA

TI - (A B)
Human miR-1236 **antisense** ribonucleic acid and application thereof

AB - (A)
The invention discloses an **antisense oligonucleotide** for inhibiting human microRNA-1236 expression and application thereof. The **antisense oligonucleotide** is specifically combined with human miR-1236 and comprises sequences which **complement** at least 13 continuous nucleotides in the nucleotide sequence of 5'-CCUCUCCCCUUGUCUCUCCAG-3', especially the sequence of 5'-CUGGAGAGACAAGGGGAAGAGG-3'. The **antisense oligonucleotide** can be ribonucleotide, deoxyribonucleotide or chimera thereof, and any nucleotide in the strand can be **modified**. The human miR-1236 **antisense** ribonucleic acid in the invention can inhibit miR-1236 expressions in glioma cells of human brains and inhibit the growth and multiplication of the cells, thereby effectively treating glioma tumors and other tumors with high miR-1236 expression.

Búsqueda STN

STN Search Queries

- L1** **Initial Search:** 27-Apr-2018 06:58 PM EDT **Last Search:** 27-Apr-2018 06:58 PM EDT
- ("complement")/BI OR ("Complement factor B" OR "Complement inhibitors")/CT
- User Settings:** Abbreviations=on; Plurals=on; Spelling=on; Apostrophe=on; Chemical Names=on; Diacritics=on; Hyphen=on; Cross File=on
- CAplus: 138038 REGISTRY: 1681253
- L2** **Initial Search:** 27-Apr-2018 07:01 PM EDT **Last Search:** 27-Apr-2018 07:01 PM EDT
- L1** and (("gapmer" OR "gapmers")/BI OR ("oligonucleotide")/BI OR ("Oligomer" OR "Oligomers")/CT)
- User Settings:** Abbreviations=on; Plurals=on; Spelling=on; Apostrophe=on; Chemical Names=on; Diacritics=on; Hyphen=on; Cross File=on
- CAplus: 2016 REGISTRY: 306836
- L3** **Initial Search:** 27-Apr-2018 07:01 PM EDT **Last Search:** 27-Apr-2018 07:04 PM EDT
- L1** and ("gapmer" OR "gapmers")/BI
- User Settings:** Abbreviations=on; Plurals=on; Spelling=on; Apostrophe=on; Chemical Names=on; Diacritics=on; Hyphen=on; Cross File=on
- CAplus: 5 REGISTRY: 1203
- L4** **Initial Search:** 27-Apr-2018 07:04 PM EDT **Last Search:** 27-Apr-2018 07:04 PM EDT
- refx 1676122-96-5/rn
- User Settings:** Abbreviations=on; Plurals=on; Spelling=on; Apostrophe=on; Chemical Names=on; Diacritics=on; Hyphen=on; Cross File=on
- CAplus: 1 REGISTRY: -
- L5** **Initial Search:** 27-Apr-2018 07:06 PM EDT **Last Search:** 27-Apr-2018 07:06 PM EDT
- L1** and ("antisensenucleic" OR "antisenseoligonucleotide" OR "antisenseoligonucleotides" OR "antisenseoligonucleotide")/BI
- User Settings:** Abbreviations=on; Plurals=on; Spelling=on; Apostrophe=on; Chemical Names=on; Diacritics=on; Hyphen=on; Cross File=on